SCHEMBL3273799

SCHEMBL3273799

COCCNc1cc(NCc2ccc(F)cc2OC)nc2ccc(NCc3ccccc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
DHFR P00374 3/20 0.43
PDGFRB P09619 2/20 0.41
PDGFRA P16234 2/20 0.41
NCF1 P14598 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GPR35 Q9HC97 1/20 0.41
NTRK1 P04629 7/20 0.41
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KCNH3 Q9ULD8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3273200 0.92 ALDH1A1 (0.42) KCNH2DHFRMEN1KMT2ANTRK1
SCHEMBL3268429 0.85 DHFR (0.50) KCNH2DHFRPDGFRBPDGFRANTRK1
SCHEMBL3268562 0.84 NTRK1 (0.41) NCF1MEN1KMT2AGPR35NTRK1
SCHEMBL3267029 0.79 DHFR (0.52) DHFRMEN1KMT2ANTRK1LMNA
SCHEMBL3267162 0.79 NTRK1 (0.52) KCNH2DHFRPDGFRBPDGFRANTRK1
SCHEMBL8509984 0.78 KCNH2 (0.49) KCNH2MEN1KMT2ANTRK1LMNA
SCHEMBL3267190 0.76 DHFR (0.50) DHFRPDGFRBPDGFRAMEN1KMT2A
SCHEMBL3268616 0.72 PDGFRB (0.53) PDGFRBPDGFRAMEN1KMT2ALMNA
SCHEMBL3267094 0.72 CYP1A2 (0.47) KCNH2MEN1KMT2ANTRK1LMNA
SCHEMBL3266976 0.72 NTRK1 (0.42) PDGFRBPDGFRAMEN1KMT2AGPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US disclosed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP disclosed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088451-A1 QUINOLINES HTR5A, HTR1A, HTR1E KCNH2 524/4885DHFR 499/4885PDGFRB 777/4885
US-20120136018-A1 QUINOLINES HTR5A, HTR1A, HTR1E KCNH2 524/4885DHFR 499/4885PDGFRB 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.